What is the appropriate management for a patient with rheumatic heart disease (RHD) on anticoagulation who has atrial fibrillation (AF) with a fast ventricular response (FVR)?

Management of RHD with AF and Fast Ventricular Response

For a patient with rheumatic heart disease on anticoagulation who develops atrial fibrillation with fast ventricular response, immediately assess hemodynamic stability and use beta-blockers, digoxin, or diltiazem/verapamil (if LVEF >40%) for acute rate control, while maintaining vitamin K antagonist (VKA) anticoagulation—NOT direct oral anticoagulants (DOACs)—regardless of rhythm control success. 1, 2

Immediate Assessment and Rate Control

Hemodynamic Stability First

• If hemodynamically unstable: Proceed directly to emergent electrical cardioversion 1
• If hemodynamically stable: Initiate pharmacologic rate control as outlined below

Acute Rate Control Strategy

The 2024 ESC guidelines provide clear first-line options 1:

• Beta-blockers (safe at any ejection fraction)
• Digoxin (safe at any ejection fraction)
• Diltiazem or verapamil (only if LVEF >40%)

These agents can be used as monotherapy or in combination. Digoxin combined with beta-blockers or calcium channel blockers produces favorable outcomes, though digoxin alone is generally ineffective for acute rate control 3.

Critical Anticoagulation Management

VKAs Are Mandatory in RHD

This is the most important pitfall to avoid: DOACs are contraindicated in RHD patients with AF, even if they have moderate-to-severe mitral stenosis 1, 4.

The INVICTUS trial (2023) definitively demonstrated that rivaroxaban is inferior to VKAs in RHD-related AF for preventing stroke, systemic embolism, MI, or death 2. This reinforces guideline recommendations.

Specific Anticoagulation Requirements

• Target INR: 2.0-3.0 with time in therapeutic range >70% 1
• Continue anticoagulation for at least 3 weeks before any elective cardioversion if AF duration >24 hours 1
• Maintain anticoagulation indefinitely based on thromboembolic risk (CHA₂DS₂-VASc score), regardless of whether sinus rhythm is restored 1

The 2019 AHA/ACC/HRS guidelines explicitly exclude moderate-to-severe mitral stenosis and mechanical valves from DOAC eligibility 4, and RHD commonly involves mitral stenosis 2, 5.

Rhythm Control Considerations

When to Consider Cardioversion

After achieving rate control and ensuring adequate anticoagulation:

• Electrical cardioversion: Preferred if patient remains symptomatic despite rate control
• Pharmacological cardioversion: Alternative based on patient characteristics
• Timing: Delay cardioversion and provide ≥3 weeks of therapeutic anticoagulation if AF duration >24 hours 1

Long-term Rhythm Control

Consider rhythm control strategies primarily for:

• Symptom reduction and quality of life improvement 1
• Young, active RHD patients who may not tolerate rate control alone 5

Important caveat: RHD patients are often younger and more active than typical AF populations, making rate control alone potentially inadequate for symptom management 5.

Ongoing Management Algorithm

1. Achieve and maintain disease remission/rate control
2. Optimize anticoagulation (VKA with INR 2.0-3.0, >70% time in range)
3. Assess renal and hepatic function at least annually 4
4. Periodically reassess stroke risk, bleeding risk, and modifiable risk factors 1
5. Continue anticoagulation lifelong regardless of rhythm status 1

Common Pitfalls to Avoid

• Never switch to DOACs in RHD patients, even with good INR control—this is associated with worse outcomes 2
• Don't use digoxin monotherapy for acute rate control in FVR—it's ineffective 3
• Don't stop anticoagulation after successful cardioversion or ablation in RHD—stroke risk persists 1, 5
• Avoid combining anticoagulants with antiplatelet agents unless acute vascular event or specific procedural indication exists 1